Clinical Trials Update: July 13, 2005
Peripheral Arterial Occlusive Disease Leukemia Insomnia
(HealthDay News) -- Here are the latest clinical trials, courtesy of CenterWatch:
Peripheral Arterial Occlusive Disease
Valentis is conducting a multicenter, phase II clinical trial to evaluate the safety and efficacy of its new investigational drug, which is injected once into the leg muscles. The drug is being developed as a means to stimulate the growth of new blood vessels and alleviate the adverse effects caused by peripheral arterial disease in the legs. Participants must be men or women between 40 and 78, must give informed consent, and have a current medical history of peripheral arterial disease, which includes the following symptoms: leg pain, leg discomfort, leg weakness. Research sites located in Louisiana, Florida, Texas and Washington.
The purpose of the study is to determine the safety and efficacy of an investigational drug that is being tested in patients with different types of leukemia and blood malignancies. Participants must meet the following criteria: age 18 years or older; a history of a blood malignancy including CML, ALL, systemic mastocytosis, chronic eosinophilic leukemia or hypereosinophilic syndrome; and be able to fast for two hours prior to taking the study medication and for one hour afterward. Research sites located in Texas, Florida and Illinois.
If you have trouble falling or staying asleep, are between ages 20 and 65, and in good general health, you may be eligible to participate in a 30-day study of an investigational medication for insomnia. Compensation is $500. Research site located in Stanford, Calif.
Copyright 2005 CenterWatch. All rights reserved.